These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30867456)

  • 1. Designing novel possible kinase inhibitor derivatives as therapeutics against Mycobacterium tuberculosis: An in silico study.
    Shahbaaz M; Nkaule A; Christoffels A
    Sci Rep; 2019 Mar; 9(1):4405. PubMed ID: 30867456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening of antitubercular compound library identifies novel shikimate kinase inhibitors of Mycobacterium tuberculosis.
    Rajput VS; Mehra R; Kumar S; Nargotra A; Singh PP; Khan IA
    Appl Microbiol Biotechnol; 2016 Jun; 100(12):5415-26. PubMed ID: 26887318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations.
    Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R
    J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing the structure of Mycobacterium tuberculosis MbtA: model validation using molecular dynamics simulations and docking studies.
    Maganti L; Open Source Drug Discovery Consortium ; Ghoshal N
    J Biomol Struct Dyn; 2014; 32(2):273-88. PubMed ID: 23527569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of interactions of clinical mutants of catalase-peroxidase (KatG) responsible for isoniazid resistance in Mycobacterium tuberculosis with derivatives of isoniazid.
    Unissa AN; Doss C GP; Kumar T; Swathi S; Lakshmi AR; Hanna LE
    J Glob Antimicrob Resist; 2017 Dec; 11():57-67. PubMed ID: 28743650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug targeted virtual screening and molecular dynamics of LipU protein of Mycobacterium tuberculosis and Mycobacterium leprae.
    Kaur G; Pandey B; Kumar A; Garewal N; Grover A; Kaur J
    J Biomol Struct Dyn; 2019 Mar; 37(5):1254-1269. PubMed ID: 29557724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis.
    Gupta A; Pal SK; Pandey D; Fakir NA; Rathod S; Sinha D; SivaKumar S; Sinha P; Periera M; Balgam S; Sekar G; UmaDevi KR; Anupurba S; Nema V
    Ann Clin Microbiol Antimicrob; 2017 Aug; 16(1):56. PubMed ID: 28821299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of First-Line Drug Resistance Mutations and Drug-Protein Interaction Dynamics from Tuberculosis Patients in South India.
    Nachappa SA; Neelambike SM; Amruthavalli C; Ramachandra NB
    Microb Drug Resist; 2018 May; 24(4):377-385. PubMed ID: 28813625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of potent chemical antituberculosis agents targeting Mycobacterium tuberculosis acetohydroxyacid synthase.
    Jung IP; Ha NR; Lee SC; Ryoo SW; Yoon MY
    Int J Antimicrob Agents; 2016 Sep; 48(3):247-58. PubMed ID: 27451857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
    Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
    Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.
    Rodrigues MO; Cantos JB; D'Oca CR; Soares KL; Coelho TS; Piovesan LA; Russowsky D; da Silva PA; D'Oca MG
    Bioorg Med Chem; 2013 Nov; 21(22):6910-4. PubMed ID: 24103427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based discovery of phenyl-diketo acids derivatives as
    Shukla R; Shukla H; Tripathi T
    J Biomol Struct Dyn; 2021 May; 39(8):2945-2958. PubMed ID: 32306850
    [No Abstract]   [Full Text] [Related]  

  • 14.
    Jagadeb M; Rath SN; Sonawane A
    J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis.
    De Logu A; Onnis V; Saddi B; Congiu C; Schivo ML; Cocco MT
    J Antimicrob Chemother; 2002 Feb; 49(2):275-82. PubMed ID: 11815568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of potent L,D-transpeptidase 5 inhibitors for Mycobacterium tuberculosis as potential anti-TB leads: virtual screening and molecular dynamics simulations.
    Sabe VT; Tolufashe GF; Ibeji CU; Maseko SB; Govender T; Maguire GEM; Lamichhane G; Honarparvar B; Kruger HG
    J Mol Model; 2019 Oct; 25(11):328. PubMed ID: 31656981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An integrated computational approach of molecular dynamics simulations, receptor binding studies and pharmacophore mapping analysis in search of potent inhibitors against tuberculosis.
    Agarwal S; Verma E; Kumar V; Lall N; Sau S; Iyer AK; Kashaw SK
    J Mol Graph Model; 2018 Aug; 83():17-32. PubMed ID: 29753941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Emergent strains of rifampicin-resistant Mycobacterium tuberculosis complex and susceptibility to isoniazid].
    Cacho-Calvo J; Martín-Díaz A;
    Enferm Infecc Microbiol Clin; 2013; 31(7):486-7. PubMed ID: 23623580
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-tubercular Modelling via QSAR Approach, In Silico Design and Virtual Docking Screening of Designed Hypothetical Inhibitors Against DNA gyrase Protein.
    Adeniji SE
    Curr Comput Aided Drug Des; 2021; 17(6):739-758. PubMed ID: 32586260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
    Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S
    BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.